PDT vs Peels for Treatment of Actinic Keratoses
Launched by NORTHWESTERN UNIVERSITY · Jun 10, 2020
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring two different treatments for actinic keratoses, which are rough patches on the skin caused by sun damage. The study is comparing photodynamic therapy (PDT), a light-based treatment, with a combination of two chemical peels, Jessner's solution and 35% trichloroacetic acid (TCA). About 60 participants, who have actinic keratoses on both of their upper arms, will receive one treatment on one arm and the other treatment on the opposite arm. Researchers will count how many actinic keratoses are left before treatment and again 2 to 8 weeks after treatment to see which method works better.
To join the study, participants must be at least 18 years old, interested in treating their actinic keratoses on both arms, and in good overall health. They also need to be able to understand and sign a consent form. Unfortunately, individuals who are pregnant or nursing, have other major skin conditions on their arms, or have difficulty communicating may not be eligible. This trial is currently not recruiting participants, but it aims to help doctors understand which treatment might be more effective for patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. \>18 years of age
- • 2. Interested in receiving treatment for actinic keratoses on the bilateral upper arms
- • 3. In good general health as assessed by the investigator
- • 4. Participants must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
- Exclusion Criteria:
- • 1. Patient pregnant or nursing
- • 2. Patient with extensive concurrent skin conditions (such as eczema, psoriasis, etc) on upper extremities that would interfere with treatment as determined by the treating physician
- • 3. Subject unwilling to sign an IRB approved consent form
- • 4. Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible
About Northwestern University
Northwestern University is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a robust infrastructure that supports interdisciplinary collaboration, Northwestern leverages its expertise in various fields, including medicine, engineering, and social sciences, to drive groundbreaking studies. The university is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring that all clinical trials are conducted with the utmost integrity and focus on participant safety. Through its Clinical Trials Office, Northwestern aims to translate scientific discoveries into effective therapies, ultimately enhancing health outcomes and contributing to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Murad Alam, MD
Principal Investigator
Northwestern University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials